Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1976 1
1978 1
1980 1
1982 3
1983 4
1984 6
1986 2
1987 3
1988 1
1989 1
1990 3
1991 4
1992 5
1993 1
1995 2
1996 4
1997 2
1998 2
1999 1
2000 5
2001 3
2002 2
2003 3
2005 1
2006 2
2007 6
2008 2
2009 4
2010 3
2011 6
2012 6
2013 3
2014 6
2015 1
2016 3
2017 5
2018 3
2019 8
2020 2
2021 2
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Malignant hyperthermia, susceptibility to, 2"
Page 1
Malignant hyperthermia.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Rosenberg H, et al. Orphanet J Rare Dis. 2007 Apr 24;2:21. doi: 10.1186/1750-1172-2-21. Orphanet J Rare Dis. 2007. PMID: 17456235 Free PMC article. Review.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely, i …
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to pot …
The myotonias and susceptibility to malignant hyperthermia.
Parness J, Bandschapp O, Girard T. Parness J, et al. Anesth Analg. 2009 Oct;109(4):1054-64. doi: 10.1213/ane.0b013e3181a7c8e5. Anesth Analg. 2009. PMID: 19762732 Review.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle in which volatile anesthetics trigger a sustained increase in intramyoplasmic Ca(2+) via release from sarcoplasmic reticulum and, possibly, entry from the extracellular milieu that l …
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle in which volatile anesthetics trigger a sustained …
Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study.
Klingler W, Heiderich S, Girard T, Gravino E, Heffron JJ, Johannsen S, Jurkat-Rott K, Rüffert H, Schuster F, Snoeck M, Sorrentino V, Tegazzin V, Lehmann-Horn F. Klingler W, et al. Orphanet J Rare Dis. 2014 Jan 16;9:8. doi: 10.1186/1750-1172-9-8. Orphanet J Rare Dis. 2014. PMID: 24433488 Free PMC article.
BACKGROUND: Malignant hyperthermia (MH) is a rare pharmacogenetic disorder which is characterized by life-threatening metabolic crises during general anesthesia. ...METHODS: In a multi-centre study including seven European MH units, patients with a history of a c …
BACKGROUND: Malignant hyperthermia (MH) is a rare pharmacogenetic disorder which is characterized by life-threatening metaboli …
Malignant hyperthermia.
Marmor M. Marmor M. Surv Ophthalmol. 1983 Sep-Oct;28(2):117-27. doi: 10.1016/0039-6257(83)90081-4. Surv Ophthalmol. 1983. PMID: 6359512 Review.
Malignant hyperthermia is a potentially fatal complication of general anesthesia that may occur with greater frequency in some patients with ptosis or strabismus. ...A protocol for the treatment of the acute malignant hyperthermia crisis and guidelines …
Malignant hyperthermia is a potentially fatal complication of general anesthesia that may occur with greater frequency in some …
Clinical protocol for the management of malignant hyperthermia.
Kollmann-Camaiora A, Alsina E, Domínguez A, Del Blanco B, Yepes MJ, Guerrero JL, García A. Kollmann-Camaiora A, et al. Rev Esp Anestesiol Reanim. 2017 Jan;64(1):32-40. doi: 10.1016/j.redar.2016.06.004. Epub 2016 Sep 12. Rev Esp Anestesiol Reanim. 2017. PMID: 27633384 Review. English, Spanish.
Malignant hyperthermia is a hypermetabolic syndrome that appears in susceptible patients after exposure to certain anaesthetic drugs (succinylcholine, inhalation anaesthetics). ...It is induced by an abnormal regulation of the ryanodine receptors, producing a …
Malignant hyperthermia is a hypermetabolic syndrome that appears in susceptible patients after exposure to certain anae …
Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH).
Riazi S, Bersselaar LRVD, Islander G, Heytens L, Snoeck MMJ, Bjorksten A, Gillies R, Dranitsaris G, Hellblom A, Treves S, Kunst G, Voermans NC, Jungbluth H. Riazi S, et al. Neuromuscul Disord. 2022 Aug;32(8):628-634. doi: 10.1016/j.nmd.2022.06.003. Epub 2022 Jun 11. Neuromuscul Disord. 2022. PMID: 35738978 Free article.
Malignant hyperthermia (MH) is a life-threatening reaction triggered by volatile anesthetics and succinylcholine. ...We investigated the role of pre-operative exercise and pyrexia as potential MH modifying factors. We included cases from 5 MH referral centers with 1 …
Malignant hyperthermia (MH) is a life-threatening reaction triggered by volatile anesthetics and succinylcholine. ...We invest …
Malignant hyperthermia.
Willner J. Willner J. Pediatr Ann. 1984 Feb;13(2):128, 130, 132-4. Pediatr Ann. 1984. PMID: 6369232 Review. No abstract available.
Prevalence of malignant hyperthermia diagnosis in obstetric patients in the United States, 2003 to 2014.
Guglielminotti J, Rosenberg H, Li G. Guglielminotti J, et al. BMC Anesthesiol. 2020 Jan 20;20(1):19. doi: 10.1186/s12871-020-0934-0. BMC Anesthesiol. 2020. PMID: 31959119 Free PMC article.
BACKGROUND: The cost-benefit of stocking dantrolene in maternity units for treating malignant hyperthermia (MH) has been recently questioned because of the low incidence of MH crisis in the general population and the low utilization of general anesthesia in obstetri …
BACKGROUND: The cost-benefit of stocking dantrolene in maternity units for treating malignant hyperthermia (MH) has been recen …
Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia.
Litman RS, Smith VI, Larach MG, Mayes L, Shukry M, Theroux MC, Watt S, Wong CA. Litman RS, et al. Anesth Analg. 2019 Apr;128(4):652-659. doi: 10.1213/ANE.0000000000004039. Anesth Analg. 2019. PMID: 30768455
At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unresolved clinical questions concerning the optimal management of patients with malignant hyperthermia (MH) susceptibilit …
At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unreso …
Myotoxicity of local anesthetics is equivalent in individuals with and without predisposition to malignant hyperthermia.
Otsuki S, Yasuda T, Mukaida K, Noda Y, Kanzaki R, Miyoshi H, Kondo T, Hamada H, Kawamoto M. Otsuki S, et al. J Anesth. 2018 Aug;32(4):616-623. doi: 10.1007/s00540-018-2526-4. Epub 2018 Jun 25. J Anesth. 2018. PMID: 29938387
PURPOSE: Malignant hyperthermia (MH) is an inherited muscle disorder caused by abnormal elevations of intracellular calcium (Ca(2+)) in skeletal muscle. ...METHODS: Human skeletal muscle samples were obtained from 22 individuals to determine susceptibility …
PURPOSE: Malignant hyperthermia (MH) is an inherited muscle disorder caused by abnormal elevations of intracellular calcium (C …
123 results